Loading clinical trials...
Loading clinical trials...
Phase I, Open-label, 3-way Crossover Trial in Healthy Volunteers to Determine the Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
Conditions
Interventions
TMC435350
Rifampin
+1 more
Start Date
June 1, 2008
Primary Completion Date
December 1, 2008
Completion Date
December 1, 2008
Last Updated
April 18, 2013
NCT06192160
NCT05947890
NCT05989802
NCT02354014
NCT06272812
NCT06953479
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions